Gastroparesis Drug Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Gastroparesis Drug Market is segmented by Drug Class (Antiemetic Agents, Prokinetic Agents, Botulinum Toxin Injections), by Disease Type (Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis), by End User (Hospitals, Clinics, Pharmacies), and Geography.

Market Snapshot

Gastroparesis Drug Market Overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 4.5 %
Gastroparesis Drug Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The gastroparesis drug market is expected to register a CAGR of 4.5% during the forecast period. Several factors, such as the increase in the incidence rate of diabetic population, rise in the number of surgical procedures, and growth in geriatric population are among the key driving factors for the gastroparesis drug market. Gastroparesis is a disorder affecting mostly type1 and type2 diabetic patients. In this disorder, the stomach takes too long to empty its contents. Drugs, such as erythromycin, antiemetics, and Reglan are prescribed for treating gastroparesis. Moreover, there are 119 completed and ongoing clinical trials for gastroparesis drugs due to high prevalence of type1 and type2 diabetes which may further have high chances of having gastroparesis. This drives the demand for these drugs and will further fuel the overall market to a certain extent. However, side effects related to gastroparesis drugs may hamper the market.

Scope of the Report

Gastroparesis drug is a medication to treat gastroparesis disorder, which in other name means “stomach paralysis”. It affects the stomach muscles which lead to restriction of proper digestion and causes vomiting and problems related to blood sugar level. Gastroparesis drug market is segmented by drug class, disease type, and geography.

By Drug Class
Antiemetic Agents
Prokinetic Agents
Botulinum Toxin Injections
By Disease Type
Diabetic Gastroparesis
Post-Surgical Gastroparesis
Idiopathic Gastroparesis
Other Disease Types
By End User
Hospitals
Clinics
Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Idiopathic Gastroparesis Segment is Expected to Contribute a largest segment in the Gastroparesis Drug Market.

  • Idiopathic gastroparesis is growing at a good rate as this disease is a very common category in gastroparesis, wherein cause is unknown and symptoms are vomiting, nausea, upper abdominal pain. These symptoms can be cured by dietary modification, antiemetic drug therapy, prokinetics medication, and symptoms modulators. This further results in the adoption of gastroparesis drugs and will drive the market to a certain extent. Prokinetics drugs will also enhance the gastrointestinal motility by increasing the frequency of contraction and propel the growth of gastroparesis drug market.
  • In addition, with the growing number of diabetes Mellitus population worldwide, leading to high demand for diagnosis and treatment and as diabetes is a common cause of gastroparesis condition, thus propelling the gastroparesis drug market.
Gastroparesis Drug Market Key Trends

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the gastroparesis drug market due to the increasing aging population and the rising number of surgical procedures. For instance, according to the Centers for Disease Control and Prevention in 2019, around 84 million people have prediabetics, which leads to the prevalence of gastroparesis disorder and will drive the gastroparesis drug market. Furthermore, increasing healthcare expenditure, a growing number of hospitals and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Asia- Pacific regions will also show a lucrative opportunity for many companies as countries like India have a high prevalence rate of diabetes which further leads to gastroparesis disorder and will contribute to the gastroparesis drug market.

Gastroparesis Drug Market Growth Rate

Competitive Landscape

Some of the companies which are currently dominating the market are Abbott (Abbott Arzneimittel GmbH), Allergan, Cadila Pharmaceuticals, Evoke Pharma, AstraZeneca, Neurogastrx, Inc, Bausch Health, Theravance Biopharma, and GlaxoSmithKline plc.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase in the Incidence Rate of Diabetes

      2. 4.2.2 Rise in Number of Surgeries

      3. 4.2.3 Growth in Geriatric Population

    3. 4.3 Market Restraints

      1. 4.3.1 Time-consuming Regulatory Process

      2. 4.3.2 Side Effects of Gastroparesis Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Class

      1. 5.1.1 Antiemetic Agents

      2. 5.1.2 Prokinetic Agents

      3. 5.1.3 Botulinum Toxin Injections

    2. 5.2 By Disease Type

      1. 5.2.1 Diabetic Gastroparesis

      2. 5.2.2 Post-Surgical Gastroparesis

      3. 5.2.3 Idiopathic Gastroparesis

      4. 5.2.4 Other Disease Types

    3. 5.3 By End User

      1. 5.3.1 Hospitals

      2. 5.3.2 Clinics

      3. 5.3.3 Pharmacies

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott (Abbott Arzneimittel GmbH)

      2. 6.1.2 Allergan Plc

      3. 6.1.3 Cadila Pharmaceuticals

      4. 6.1.4 Evoke Pharma

      5. 6.1.5 AstraZeneca Plc

      6. 6.1.6 Neurogastrx Inc.

      7. 6.1.7 Bausch Health

      8. 6.1.8 Theravance Biopharma

      9. 6.1.9 GlaxoSmithKline Plc

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Gastroparesis Drug Market market is studied from 2018 - 2026.

The Gastroparesis Drug Market is growing at a CAGR of 4.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Allergan, Evoke Pharma, AstraZeneca, Cadila Pharmaceuticals, Neurogastrx, Inc. are the major companies operating in Gastroparesis Drug Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!